Table 1 Baseline demographic and disease characteristics
Lanreotide autogel (N = 64) | Lanreotide 40 mg PR (N = 64) | All patients (N = 128) | |
|---|---|---|---|
Age, years | |||
Mean (SD) | 37.9 (11.2) | 40.8 (12.6) | 39.4 (11.9) |
Sex, n (%) | |||
Male | 26 (40.6) | 24 (37.5) | 50 (39.1) |
Female | 38 (59.4) | 40 (62.5) | 78 (60.9) |
BMI, kg/m2 | |||
Mean (SD) | 26.3 (3.6) | 26.1 (3.6) | 26.2 (3.6) |
Time since acromegaly, years | |||
Mean (SD) | 3.70 (5.83) | 3.14 (4.09) | 3.42 (5.02) |
Previous treatment, n (%) | |||
Pituitary surgery | 44 (68.8) | 44 (68.8) | 88 (68.8) |
Radiotherapy | 3 (4.7) | 3 (4.7) | 6 (4.7) |
Any acromegaly medication ≤ 6 months prior to study entry, n (%) | 10 (15.6) | 12 (18.8) | 22 (17.2) |
Tumor assessment at baseline by central evaluation, n (%) | (n = 63) | (n = 64) | (n = 127) |
Microadenomaa | 15 (23.4) | 12 (18.8) | 27 (21.1) |
Macroadenomaa | 43 (67.2) | 47 (73.4) | 90 (70.3) |
No tumor | 5 (7.8) | 5 (7.8) | 10 (7.8)b |
Solid component (μL) | (n = 58) | (n = 57) | (n = 115) |
Mean (SD) | 4990.5 (8752.8) | 2589.1 (2666.5) | 3800.2 (6576.7) |